Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/44/1e/84/441e8404-cfcd-d5ea-5cd7-20bcae5f4165/mza_9369316362601325051.jpg/600x600bb.jpg

WolverHeme Happy Hour

Bernard Marini, Anthony Perissinotti, et al.

41 episodes

2 weeks ago

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

Medicine

Health & Fitness

RSS

All content for WolverHeme Happy Hour is the property of Bernard Marini, Anthony Perissinotti, et al. and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/22883740/22883740-1646962011003-b3603219ae0ba.jpg

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

WolverHeme Happy Hour

48 minutes 7 seconds

1 year ago

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

In this episode, Bernie and Anthony are joined by two special guest expert hematologists:

Dr. David Russler-Germain

Dr. Tycel Phillips

We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?

Stay tuned to find out!